Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
Launched by UNIVERSITY OF WASHINGTON · Apr 10, 2009
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
CHD is the leading cause of death in the United States. Preliminary research has shown that CHD is associated with oxidative and inflammatory changes in high-density lipoprotein (HDL) cholesterol, which is considered the "good" cholesterol. The inflammatory changes can impair HDL cholesterol's normal function, which is to remove excess cholesterol from the arteries and thereby slow the build-up of atherosclerotic plaque. Statins are cholesterol-lowering medications that are used to treat people with CHD. Taking niacin, a type of B vitamin, in combination with statins may stabilize atheroscl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligible for main AIM-HIGH study (NCT00120289)
- • Willing to provide informed consent for participation in this substudy
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Houston, Texas, United States
Baltimore, Maryland, United States
Seattle, Washington, United States
Seattle, Washington, United States
Houston, Texas, United States
Durham, North Carolina, United States
Philadelphia, Pennsylvania, United States
Portland, Oregon, United States
Long Beach, California, United States
Richmond, Virginia, United States
Newark, Delaware, United States
Minneapolis, Minnesota, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Minneapolis, Minnesota, United States
Birmingham, Alabama, United States
Calgary, Alberta, Canada
Phoenix, Arizona, United States
Greensboro, North Carolina, United States
Winston Salem, North Carolina, United States
Winston Salem, North Carolina, United States
Cleveland, Ohio, United States
Houston, Texas, United States
Seattle, Washington, United States
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Kevin D. O'Brien, MD
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials